Q-omics provides the consensus-scored ZHX1 profile across patient tissues and cancer cell-line models. ZHX1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZHX1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZHX1 RNA expression shows 20,339 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZHX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZHX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZHX1 survival associations across molecular data types. ZHX1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZHX1 RNA expression–survival associations across cancer types. High ZHX1 expression shows unfavorable associations in ACC, UCEC, CESC and BRCA, but favorable associations in KIRC and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZHX1 RNA expression.
This table summarizes ZHX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZHX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZHX1 shows lower tumor expression in THCA, KIRP, UCEC, KIRC and COAD and higher tumor expression in LIHC. The THCA box plot shows higher ZHX1 RNA expression in normal versus tumor tissue (log2 FC = −0.866, t-test p < 0.001).
This table shows molecular features associated with ZHX1 in patient tissues and cancer cell lines. In patient samples, ZHX1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZHX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
